A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Reilly, Shannon M ^a   Ahmadian, Maryam ^b   Zamarron, Brian F ^a   Chang, Louise ^a   Uhm, Maeran ^a   Poirier, Breanne ^a   Peng, Xiaoling ^a   Krause, Danielle M ^a   Korytnaya, Evgenia ^a   Neidert, Adam ^a   Liddle, Christopher ^b,c   Yu, Ruth T ^b   Lumeng, Carey N ^a   Oral, Elif A ^a   Downes, Michael ^b   Evans, Ronald M ^b   Saltiel, Alan R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLEXANOX; CYCLIC AMP; I KAPPA B KINASE EPSILON; INTERLEUKIN 6; STAT3 PROTEIN; AMINOPYRIDINE DERIVATIVE; BETA ADRENERGIC RECEPTOR; GLUCOSE 6 PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

DIABETES; GLUCOSE; INHIBITION; METABOLISM; OBESITY; PHOSPHORUS; SIGNALING;

ADIPOCYTE; ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROADIPOCYTE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; SYNTHESIS; TREATMENT OUTCOME; 3T3 CELL LINE; ANIMAL; C57BL MOUSE; CLINICAL TRIAL; DRUG EFFECTS; GENE SILENCING; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

MUS;

3T3-L1 CELLS; ADIPOCYTES; ADULT; AGED; AMINOPYRIDINES; ANIMALS; CYCLIC AMP; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLUCONEOGENESIS; GLUCOSE-6-PHOSPHATASE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUBCUTANEOUS FAT; YOUNG ADULT;

EID: 84923110854     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7047     Document Type: Article

References (46)

1. Baker, R. G., Hayden, M. S. & Ghosh, S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 13, 11-22 (2011).
2. Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183-190 (2005).
3. Arkan, M. C. et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191-198 (2005).
4. Kravchenko, V. V., Mathison, J. C., Schwamborn, K., Mercurio, F. & Ulevitch, R. J. IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J. Biol. Chem. 278, 26612-26619 (2003).
5. Saltiel, A. R. Insulin resistance in the defense against obesity. Cell Metab. 15, 798-804 (2012).
6. Chiang, S. H. et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 138, 961-975 (2009).
7. Perkins, N. D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8, 49-62 (2007).
8. Mowers, J. et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKK{varepsilon} and TBK1. Elife 2, e01119 (2013).
9. Bougneres, P. et al. In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. J. Clin. Invest. 99, 2568-2573 (1997).
10. Collins, S., Daniel, K. W., Petro, A. E. & Surwit, R. S. Strain-specific response to beta 3-adrenergic receptor agonist treatment of diet-induced obesity in mice. Endocrinology 138, 405-413 (1997).
11. Surwit, R. S., Dixon, T. M., Petro, A. E., Daniel, K. W. & Collins, S. Diazoxide restores beta3-adrenergic receptor function in diet-induced obesity and diabetes. Endocrinology 141, 3630-3637 (2000).
12. Kush, R. D. et al. Effect of diet on energy expenditure and plasma norepinephrine in lean and obese Pima Indians. Metabolism 35, 1110-1120 (1986).
13. Reilly, S. M. et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat. Med. 19, 313-321 (2013).
14. Cao, W. et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol. Cell Biol. 24, 3057-3067 (2004).
15. Robidoux, J. et al. Selective activation of mitogen-activated protein (MAP) kinase kinase 3 and p38alpha MAP kinase is essential for cyclic AMPdependent UCP1 expression in adipocytes. Mol. Cell Biol. 25, 5466-5479 (2005).
16. Cao, W., Medvedev, A. V., Daniel, K. W. & Collins, S. beta-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase. J. Biol. Chem. 276, 27077-27082 (2001).
17. Mohamed-Ali, V. et al. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 86, 5864-5869 (2001).
18. Tchivileva, I. E. et al. Signaling pathways mediating beta3-adrenergic receptorinduced production of interleukin-6 in adipocytes. Mol. Immunol. 46, 2256-2266 (2009).
19. Yin, F. et al. Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J. Mol. Cell. Cardiol. 40, 384-393 (2006).
20. Tan, K. S. et al. Beta2 adrenergic receptor activation stimulates proinflammatory cytokine production in macrophages via PKA-and NF-kappaBindependent mechanisms. Cell Signal 19, 251-260 (2007).
21. Ramadoss, P., Unger-Smith, N. E., Lam, F. S. & Hollenberg, A. N. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol. Endocrinol. 23, 827-837 (2009).
22. Inoue, H. et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 10, 168-174 (2004).
23. Inoue, H. et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 3, 267-275 (2006).
24. Mauer, J. et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423-430 (2014).
25. Wunderlich, F. T. et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12, 237-249 (2010).
26. Haffner, S. M., Miettinen, H. & Stern, M. P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20, 1087-1092 (1997).
27. Katsuki, A. et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24, 362-365 (2001).
28. Ikeda, Y., Suehiro, T., Nakamura, T., Kumon, Y. & Hashimoto, K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr. J. 48, 81-86 (2001).
29. Fisman, E. Z. & Tenenbaum, A. The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc. Diabetol. 9, 62 (2010).
30. Pickup, J. C., Mattock, M. B., Chusney, G. D. & Burt, D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40, 1286-1292 (1997).
31. Kern, P. A., Ranganathan, S., Li, C., Wood, L. & Ranganathan, G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280, E745-E751 (2001).
32. Vozarova, B. et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9, 414-417 (2001).
33. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. & Ridker, P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334 (2001).
34. Senn, J. J., Klover, P. J., Nowak, I. A. & Mooney, R. A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51, 3391-3399 (2002).
35. Gwozdziewiczova, S., Lichnovska, R., Ben Yahia, R., Chlup, R. & Hrebicek, J. TNF-alpha in the development of insulin resistance and other disorders in metabolic syndrome. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 149, 109-117 (2005).
36. Matthews, V. B. et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53, 2431-2441 (2010).
37. Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75-79 (2002).
38. Carey, A. L. et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55, 2688-2697 (2006).
39. Burysek, L. & Houstek, J. beta-Adrenergic stimulation of interleukin-1alpha and interleukin-6 expression in mouse brown adipocytes. FEBS Lett. 411, 83-86 (1997).
40. Northoff, H. & Berg, A. Immunologic mediators as parameters of the reaction to strenuous exercise. Int. J. Sports Med. 12(Suppl 1): S9-15 (1991).
41. Ostrowski, K., Rohde, T., Asp, S., Schjerling, P. & Pedersen, B. K. Pro-and anti-inflammatory cytokine balance in strenuous exercise in humans. J. Physiol. 515(Pt 1), 287-291 (1999).
42. Helge, J. W. et al. The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle. J. Physiol. 546, 299-305 (2003).
43. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
44. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
45. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
46. Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207-210 (2002).